Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/24 08:07:33 pm
60.77 USD   -0.70%
08:03p MERCK : Seminole Management Co. Inc. Invests $19,783,000 in Merck & ..
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to..
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.


-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
08:03p MERCK : Seminole Management Co. Inc. Invests $19,783,000 in Merck & Co. (MRK)
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/22 MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
10/20 MERCK : Studies from Merck Research Labs in the Area of Thrombosis Reported (Dif..
10/20MERCK & CO., INC. : quaterly earnings release
10/19 MERCK : Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antivi..
More news
Sector news : Pharmaceuticals - NEC
04:32pDJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
12:46pDJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:11a BIOTECH FORUM DAILY DIGEST : Election Worries Overblown? Spotlight On Akorn
07:01a Glaxo submits BLA for shingles vaccine in U.S.
10/22 FDA OKs Merck's bezlotoxumab to reduce recurrence of C. diff infection in cer..
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
Financials ($)
Sales 2016 39 696 M
EBIT 2016 13 597 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,97%
P/E ratio 2016 30,00
P/E ratio 2017 19,78
EV / Sales 2016 4,40x
EV / Sales 2017 4,30x
Capitalization 169 231 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.87%169 231
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
More Results